Oculis (NASDAQ:OCS – Get Free Report) and Immunome (NASDAQ:IMNM – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.
Valuation and Earnings
This table compares Oculis and Immunome”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Oculis | $980,000.00 | 916.30 | -$98.92 million | ($1.93) | -11.49 |
Immunome | $10.13 million | 62.30 | -$106.81 million | ($8.11) | -1.25 |
Oculis has higher earnings, but lower revenue than Immunome. Oculis is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Analyst Recommendations
This is a breakdown of current recommendations for Oculis and Immunome, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Oculis | 0 | 0 | 5 | 0 | 3.00 |
Immunome | 0 | 0 | 7 | 0 | 3.00 |
Oculis presently has a consensus price target of $28.80, indicating a potential upside of 29.91%. Immunome has a consensus price target of $28.83, indicating a potential upside of 185.20%. Given Immunome’s higher probable upside, analysts plainly believe Immunome is more favorable than Oculis.
Profitability
This table compares Oculis and Immunome’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Oculis | -8,043.28% | -71.31% | -56.85% |
Immunome | -3,014.59% | -48.63% | -41.62% |
Insider & Institutional Ownership
22.3% of Oculis shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 8.6% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Immunome beats Oculis on 10 of the 13 factors compared between the two stocks.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
About Immunome
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.